Diagnostic power of vertebral hydroxyapatite concentration measurements in spectral CT for osteoporosis-associated fractures and impact of intravenous contrast administration

• Published in: European radiology 2023-06, Vol.33 (6), p.4016-4023
• Main Authors: Ma, Qiang, Hou, Xinmeng, Zhao, Chenglin, Yan, Yuanyuan, Cheng, Xiaoyue, Li, Jianying, Ma, Daqing, Yang, Zhenghan
• Format: Article
• Language: English
• Subjects: Absorptiometry, Photon - methods; Bone Density; Computed tomography; Diagnostic Radiology; Diagnostic systems; Effectiveness; Electronic health records; Electronic medical records; Evaluation; Female; Fractures; Humans; Hydroxyapatite; Hydroxyapatites; Image contrast; Image enhancement; Imaging; Information systems; Internal Medicine; Interventional Radiology; Lumbar Vertebrae - injuries; Male; Medical diagnosis; Medical imaging; Medicine; Medicine & Public Health; Middle Aged; Musculoskeletal; Neuroradiology; Osteoporosis; Osteoporosis - complications; Osteoporosis - diagnostic imaging; Osteoporotic Fractures - diagnostic imaging; Osteoporotic Fractures - epidemiology; Radiology; Retrospective Studies; Risk; Sensitivity; Spinal Fractures - diagnostic imaging; Tomography, X-Ray Computed - methods; Ultrasound; Vertebrae
• ISSN: 1432-1084; 0938-7994; 1432-1084
• DOI: 10.1007/s00330-022-09383-1

Objectives To evaluate the diagnostic power of using vertebral hydroxyapatite concentration measurements in unenhanced and contrast-enhanced spectral CT for detecting and predicting the risk of osteoporosis-associated fractures. Methods L1 of 210 patients (105 men, 105 women; mean age, 64 years, range, 19–103 years) who had undergone spectral CT examinations from January 1, 2018, to March 1, 2019, were retrospectively analyzed. Patient data for 3 years after spectral CT were retrieved from electronic medical record information systems to obtain the incidence of osteoporotic fractures. Baseline vertebral cancellous hydroxyapatite concentration from unenhanced and contrast-enhanced late-arterial-phase images was measured. The receiver operating characteristic curves were used to evaluate the diagnostic power for detecting and predicting the 3-year risk of osteoporosis-associated fractures using hydroxyapatite concentrations in both phases. Results The hydroxyapatite concentrations in both phases had good diagnostic power to detect fractures at baseline. The sensitivity and specificity for predicting one or more osteoporosis-associated fractures within 3 years after spectral CT were 76.80% and 93.10%, respectively, using the cutoff of 74.79 mg/cm 3 in vertebral hydroxyapatite concentration in the unenhanced CT phase, and 82.87% and 82.76%, respectively, using the cutoff of 84.65 mg/cm 3 in the late-arterial phase. Furthermore, there was no significant difference in the diagnosis between unenhanced and enhanced CT-derived hydroxyapatite concentrations ( p = 0.360). Conclusions Both unenhanced and enhanced spectral CT-derived hydroxyapatite concentrations can accurately detect and predict future risk of osteoporosis-associated fractures. The hydroxyapatite concentration assessed in the late-arterial phase may have a similar diagnostic efficacy to that in the unenhanced phase. Key Points • A cutoff of 74.79 mg/cm 3 of vertebral hydroxyapatite concentration in the unenhanced CT scans had 76.80% sensitivity and 93.10% specificity to predict one or more osteoporosis-associated fractures within 3 years after spectral CT examinations. • A cutoff of 84.65 mg/cm 3 of vertebral hydroxyapatite concentration in the late-arterial-enhanced CT scans had 82.87% sensitivity and 82.76% specificity to predict one or more osteoporosis-associated fractures within 3 years after spectral CT examinations. • The hydroxyapatite concentration assessed in the late-arterial phase may have